A new “risk matrix” methodology for identifying “critical medicines” in the EU. A study on optimizing public procurement of medicines to be published in the fourth quarter of 2022. And a mechanism for national authorities in Europe to further exchange information on supplies of raw materials, intermediates or active substances from different manufacturing sites.
COVID-19 & Ukraine War Underpin EU Moves To Secure Medicines Supply
Concerns by the drug industry over “complex and burdensome” regulatory requirements regarding security of supply could be addressed in the upcoming revision of the EU pharmaceutical legislation, suggests a report on the European Commission’s “structured dialog” process for tackling medicine supply chain vulnerabilities.
